NLRP3 and ischemic stroke: Nafamostat mesilate (NM), as a wide-spectrum serine protease inhibitor, has immune-modulatory impacts on ischemic stroke rats, which is related to the suppression of NLRP3 inflammasome and NF-κB signaling pathway (Li et al., 2016).